Skip to main content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

HCMG 215/863 - Management and Economics of the Pharmaceutical, Biotech & Medical Device Industries: Deals, Licensing and Policy

A note about deal and licensing information

Detailed information about licensing terms is very difficult to find. While public companies may have to report this information to the SEC if the deal is material, they can request confidential treatment of the terms, so information will often be redacted from filings.

Rare Diseases and Orphan Drug Policies

Deals & Licensing

Product Recalls